Psychedelic · MM120

Lysergide D-tartrate (MM120 / LSD)

Phase 3Definium Therapeutics, Inc. (DFTX)
  • Breakthrough Therapy

MindMed's (now Definium Therapeutics) pharmaceutically optimized lysergide (LSD) as an orally disintegrating tablet (MM120 ODT, rebranded DT120 ODT in Jan 2026). A classic serotonergic psychedelic given as a single monitored dose without adjunctive psychotherapy. Lead indication generalized anxiety disorder; also Phase 3 for MDD.

Also known as: MM120, DT120, Lysergide D-tartrate, LSD

Data current as of

Modality
Psychedelic
Chemical class
Ergoline, Lysergamide, tryptamine
DEA schedule
Schedule I
Chemistry
Single enantiomer
Mechanism
5-HT2A Partial agonist
Highest phase
Phase 3
Lead indication
Generalized anxiety disorder
Developer
Definium Therapeutics, Inc. (DFTX)
Designations
Breakthrough Therapy
Trials
5 tracked · 1 recruiting · 120 sites
Next catalyst
2027 — Registry results (Post-traumatic stress disorder)

Mechanism of action

LSD acts across serotonin receptor subtypes; the company describes MM120 as a 5-HT2A partial agonist (IUPHAR classifies LSD as a full 5-HT2A agonist). Antidepressant effects attributed primarily to 5-HT2A agonism.

TargetActionAffinity
5-HT2AprimaryHTR2APartial agonistpKi 9.4ⓘ
5-HT1AHTR1AAgonistpKi 9ⓘ
5-HT2CHTR2CAgonistpKi 8.2ⓘ

Formulations

FormulationRouteRegimenPharmacokinetics
DT120 orally disintegrating tablet (ODT)Orally disintegrating tablet (ODT) using Catalent Zydis fast-dissolve technology
Proprietary orally disintegrating tablet of lysergide (LSD) D-tartrate; single administration; designed for faster absorption and onset
OralSingle dose—
MM120 oral (Phase 2b)
Single oral dose; 25, 50, 100, or 200 µg freebase-equivalent studied in Phase 2b GAD; 100 µg selected as optimal for pivotal trials
OralSingle dose—

Development timeline

Phase 3Dec 2024 – Jan 2027
  1. UpcomingPhase 3 Haven study of DT120 ODT in PTSD expected to initiate in 2027Post-traumatic stress disorder↗
  2. Definium Therapeutics announced expansion of the DT120 ODT program into PTSD with the planned Phase 3 'Haven' study (~200 participants, 1:1 DT120 ODT vs placebo, primary endpoint CAPS-5 at Week 8), initiation expected in 2027. No NCT registered as of this record.Post-traumatic stress disorder↗
  3. Phase 3 MDD program (Emerge, NCT06941844) initiated. Date approximate.Major depressive disorder
  4. First patient dosed in Panorama (NCT06809595), second pivotal Phase 3 GAD study.Generalized anxiety disorder↗
  5. First patient dosed in Phase 3 Voyage (NCT06741228) — first-ever Phase 3 of LSD.Generalized anxiety disorder↗
DiscontinuedMar 2025
  1. missedPhase 2a microdosing trial fails: repeated low-dose MM120 (LSD) no better than placebo for adult ADHD (AISRS p=0.7145)Attention-deficit/hyperactivity disorder↗
Phase 2Dec 2023 – Mar 2024
  1. FDA Breakthrough Therapy Designation (GAD); positive 12-week durability data from the Phase 2b study.Generalized anxiety disorder↗
  2. Phase 2a proof-of-concept ADHD study (NCT05200936 / MMED007) completed (study completion date 2023-12-04; primary completion 2023-11-06).Attention-deficit/hyperactivity disorder

Lysergide D-tartrate (MM120 / LSD) for Generalized anxiety disorder

Phase 3ActiveGeneralized anxiety disorder indication →

MM120 (DT120) for generalized anxiety disorder — lead program. FDA Breakthrough Therapy granted 7 Mar 2024 on the Phase 2b dose-finding study (NCT05407064; 100 ug gave -7.7 HAM-A vs placebo at Week 12, Cohen's d 0.81). Two pivotal Phase 3 GAD studies underway: Voyage (NCT06741228) and Panorama (NCT06809595), both active, primary completion 2026. The same compound is also Phase 3 for MDD (Emerge, NCT06941844).

Lysergide D-tartrate (MM120 / LSD) for Major depressive disorder

Phase 3RecruitingMajor depressive disorder indication →

MM120 (DT120) for major depressive disorder — second indication after the lead GAD program. Phase 3 'Emerge' study (NCT06941844) evaluates a single dose for MDD. Builds on MM120's Phase 2b anxiety data and the GAD Phase 3 program (Voyage/Panorama).

Lysergide D-tartrate (MM120 / LSD) for Post-traumatic stress disorder

Phase 3ActivePost-traumatic stress disorder indication →

DT120 ODT (formerly MM120; lysergide D-tartrate / LSD) for posttraumatic stress disorder (PTSD) - the third indication after the lead GAD program (Voyage/Panorama) and MDD (Emerge/Ascend). Announced at Definium Therapeutics' April 22, 2026 Investor & Analyst Day as a planned Phase 3 study named 'Haven': ~200 participants randomized 1:1 to a single dose of DT120 ODT vs placebo, primary endpoint change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) at Week 8, study initiation expected in 2027. Not yet registered on ClinicalTrials.gov.

Readouts

  • 2027AnticipatedRegistry results

    Phase 3 Haven study of DT120 ODT in PTSD expected to initiate in 2027 ↗

Lysergide D-tartrate (MM120 / LSD) for Attention-deficit/hyperactivity disorder

DiscontinuedDiscontinuedAttention-deficit/hyperactivity disorder indication →

MM120 (lysergide / LSD; DT120) for attention-deficit/hyperactivity disorder — a deliberately tracked NEGATIVE program. The single Phase 2a proof-of-concept study (NCT05200936, study code MMED007) tested a low-dose 'microdosing' regimen (20 ug twice weekly for 6 weeks) and MISSED its primary endpoint: the change in Adult ADHD Investigator Symptom Rating Scale (AISRS) at 6 weeks did not differ from placebo (LSD -7.1 vs placebo -8.9 points; p=0.7145). Repeated low-dose LSD was safe/tolerable but showed no efficacy advantage. Results were published in JAMA Psychiatry (June 2025). MindMed (now Definium Therapeutics) did not advance MM120 to Phase 3 in ADHD, focusing instead on generalized anxiety disorder (lead) and major depressive disorder; the ADHD program is treated as discontinued.

Readouts

  • 2025-03-19ReportedFull resultsmissedNCT05200936

    Phase 2a microdosing trial fails: repeated low-dose MM120 (LSD) no better than placebo for adult ADHD (AISRS p=0.7145) ↗

Clinical trials

NCT06809595PanoramaPhase 3Activen=245

Phase 3 Study of MM120 for Generalized Anxiety Disorder (Panorama)

Started Jan 2025· Primary completion Aug 2026· 📍 37 sites across 6 countries (United States, United Kingdom, France, Germany)

NCT06741228VoyagePhase 3Activen=214

Phase 3 Study of Oral DT120 vs Placebo in Generalized Anxiety Disorder (Voyage)

Started Dec 2024· Primary completion Jul 2026· 📍 34 sites across 1 country (United States)

NCT05407064Phase 2Completedn=198

Phase 2b Dose-Finding Study of MM120 for Anxiety Symptoms

Started Aug 2022· Primary completion Oct 2023· 📍 22 sites across 1 country (United States)

metprimaryHAM-A change at Week 12 (100 ug vs placebo) — -7.7 points (Cohen's d 0.81) (<0.003)

Clinical response 65%, remission 48% at Week 12.

NCT05200936MMED007Phase 2Completedn=53

Safety and Efficacy of Repeated Low Dose d-Lysergic Acid Diethylamide (LSD) D-tartrate (MM120) as Treatment for ADHD in Adults: a Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2a Proof of Concept Trial

Started Dec 2021· Primary completion Nov 2023· 📍 2 sites across 2 countries (Netherlands, Switzerland)

missedprimaryChange from baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) total score at 6 weeks — LSD -7.1 points (95% CI -10.1 to -4.0) vs placebo -8.9 points (95% CI -12.0 to -5.8); AISRS ~37.4->29.6 (LSD) vs ~37.3->29.0 (placebo) (0.7145)

Primary endpoint MISSED. Repeated low-dose MM120 (LSD; 20 ug twice weekly x6 weeks) was not more efficacious than placebo in reducing adult ADHD symptoms on the AISRS at 6 weeks; both arms improved similarly. LSD was psychologically well tolerated and safe in an outpatient setting with no severe adverse effects, but showed no therapeutic advantage over placebo.

NCT06941844EmergePhase 3Recruiting

Phase 3 Study of MM120 (Lysergide) in Major Depressive Disorder (Emerge)

· 📍 25 sites across 1 country (United States)

Conference coverage

MM120 appears in 4 CNS Pulse conference abstracts:

Related compounds

Other 5-HT2A compounds

More from Definium Therapeutics, Inc.

  • DT402Phase 2Autism spectrum disorder

Identifiers

Sources

  1. Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day (Apr 22, 2026) — Definium Therapeutics, Inc.
  2. DT120 ODT — LSD Therapy for Depression and Anxiety — Definium Therapeutics
  3. First patient dosed in Voyage Phase 3 — MindMed / Definium
  4. clinicaltrials.gov — ClinicalTrials.gov
  5. ir.mindmed.co — Reference
  6. Lysergide (LSD), Ligand 17 — IUPHAR/BPS
  7. MindMed FDA Breakthrough + Phase 2b durability (GAD) — MindMed / Business Wire
  8. MM120 Emerge Phase 3 MDD (NCT06941844) — ClinicalTrials.gov
  9. Panorama (NCT06809595) — ClinicalTrials.gov
  10. Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial (NCT05200936 / MMED007) — ClinicalTrials.gov
  11. Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial — JAMA Psychiatry (Mueller L, et al. 2025;82(6):555-562)
  12. Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial — JAMA / PMC
  13. Voyage (NCT06741228) — ClinicalTrials.gov